NWI Management LP Boosts Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

NWI Management LP raised its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 33.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 720,000 shares of the medical research company’s stock after purchasing an additional 180,000 shares during the period. Natera accounts for about 5.0% of NWI Management LP’s portfolio, making the stock its 4th biggest position. NWI Management LP owned about 0.55% of Natera worth $113,976,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. LRI Investments LLC purchased a new stake in shares of Natera in the fourth quarter worth approximately $29,000. Blue Trust Inc. boosted its position in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after buying an additional 97 shares during the period. EverSource Wealth Advisors LLC grew its stake in Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after acquiring an additional 261 shares in the last quarter. Principal Securities Inc. increased its position in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after acquiring an additional 59 shares during the period. Finally, Steward Partners Investment Advisory LLC increased its position in shares of Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock worth $57,000 after acquiring an additional 332 shares during the period. 99.90% of the stock is owned by institutional investors.

Natera Price Performance

NASDAQ:NTRA opened at $152.28 on Wednesday. The company has a 50 day moving average price of $147.91 and a 200-day moving average price of $156.15. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00. The firm has a market cap of $20.59 billion, a price-to-earnings ratio of -86.52 and a beta of 1.79.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.09. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $501.83 million for the quarter, compared to the consensus estimate of $446.68 million. During the same period last year, the firm posted ($0.56) earnings per share. The company’s revenue was up 36.5% compared to the same quarter last year. Equities research analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Upgrades and Downgrades

NTRA has been the subject of several research reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $180.00 target price on shares of Natera in a report on Wednesday, February 26th. BTIG Research reissued a “buy” rating on shares of Natera in a research report on Friday, February 28th. Piper Sandler lifted their target price on Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. Barclays upped their price target on Natera from $160.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, May 9th. Finally, Guggenheim upped their target price on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $181.82.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 87,272 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the completion of the transaction, the chief executive officer now directly owns 203,354 shares in the company, valued at approximately $29,160,963.60. This represents a 30.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 2,206 shares of the business’s stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $152.18, for a total transaction of $335,709.08. Following the completion of the sale, the insider now directly owns 139,280 shares in the company, valued at $21,195,630.40. This trade represents a 1.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 152,436 shares of company stock worth $22,019,079. Insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.